# OnCo record paper-commands-luspatercept-mds-lancet-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-commands-luspatercept-mds-lancet-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-commands-luspatercept-mds-lancet-2023" ;
  schema:name "COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions"@en ;
  schema:description "In COMMANDS, luspatercept, a drug that frees late-stage red cell production from TGF-beta-family braking, freed 59% of transfusion-dependent MDS patients from transfusions for at least 12 weeks, against 31% with the standard erythropoietin injection."@en ;
  schema:url <https://onco.cc/key-papers/paper-commands-luspatercept-mds-lancet-2023/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=COMMANDS%20luspatercept%20epoetin%20alfa%20lower-risk%20MDS%20Platzbecker%20Lancet%202023>, <https://clinicaltrials.gov/study/NCT03682536> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(23)00874-7> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Platzbecker U, Della Porta MG, Santini V, et al." ;
  onco:related <https://onco.cc/key-papers/paper-imerge-imetelstat-mds-lancet-2024/> ;
  onco:cancers <https://onco.cc/cancers/mds/> ;
  onco:targets <https://onco.cc/pathways/tgf-beta/> ;
  onco:drugs <https://onco.cc/drugs/luspatercept/>, <https://onco.cc/drugs/imetelstat/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/orr/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-drug-pricing/> ;
  onco:journals <https://onco.cc/journals/lancet/> .